Acalabrutinib Venetoclax and Obinutuzumab for Initial Therapy of CLL
This research study is evaluating the combination of three drugs - acalabrutinib, venetoclax, and obinutuzumab -- as a possible treatment for chronic lymphocytic leukemia (CLL).
The drugs involved in this study are:
A Phase 2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) for Initial Therapy of Chronic Lymphocytic Leukemia
- ClinicalTrials.gov Identifier: NCT03580928
- Protocol Number: 18-226
- Principal Investigator: Jon Arnason
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required